Correction to: LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway

Bing Liu, Shimeng Pan, Yang Xiao, Qianqian Liu, Jingchao Xu, Jia LiJournal of Experimental & Clinical Cancer Research 2019 · DOI · OpenAlex

Introduction

This article serves as a formal correction to a 2018 study published in the Journal of Experimental & Clinical Cancer Research. The primary objective is to rectify a graphical error in Figure 5C (specifically panel 4, the InmiR-26a + silinc01296 group in SW620 cells). Beyond the correction, the data underscores a critical regulatory mechanism involving the LINC01296/miR-26a/GALNT3 axis in colorectal cancer (CRC) progression and chemoresistance.

The Molecular Mechanism: LINC01296/miR-26a/GALNT3

Colorectal cancer remains a significant global health challenge, often exacerbated by metastasis and resistance to standard treatments like 5-Fluorouracil (5-FU). This research identifies the long non-coding RNA (lncRNA) LINC01296 as a master regulator.

Following the "competitive endogenous RNA" (ceRNA) hypothesis, LINC01296 acts as a molecular "sponge," sequestering miR-26a. Under normal conditions, miR-26a suppresses oncogenic targets; however, its sequestration by LINC01296 leads to the overexpression of GALNT3. This enzyme facilitates the O-glycosylation of the MUC1 protein, which in turn activates the PI3K/AKT signaling pathway—a major driver of tumor growth and survival.

Experimental Methodology

The study utilized human CRC cell lines (SW620 and HCT-8) to map this pathway:

  • Genetic Manipulation: Researchers employed siRNAs to silence LINC01296 and miRNA mimics or inhibitors to modulate miR-26a levels.
  • Phenotypic Characterization: Cell proliferation was assessed via CCK8 and colony formation assays. Migration and invasion were quantified using Transwell assays.
  • Biochemical and Drug Sensitivity Analysis: Flow cytometry with VVA lectin detected changes in cell-surface O-linked glycosylation. Additionally, the researchers determined the $IC_{50}$ of 5-FU to evaluate how the LINC01296/miR-26a axis influences chemoresistance.

Key Results

The experimental data, consolidated in the revised Figure 5, demonstrates the profound impact of this axis on cancer cell phenotype.

Revised Figure 5 showing the functional impact of the LINC01296/miR-26a axis on CRC cell behavior and chemoresistance.
  • Proliferation and Invasion: Inhibiting miR-26a or overexpressing LINC01296 significantly enhanced the colony-forming ability and invasive potential of CRC cells. Silencing LINC01296 was shown to effectively reverse these aggressive traits (Panels B-D, J-L).
  • Glycosylation and Signaling: Flow cytometry confirmed that manipulating these factors directly alters O-linked glycosylation levels on the cell surface (Panels A, I), providing a biochemical link to the activation of downstream oncogenic pathways.
  • Chemoresistance to 5-FU: In resistant cell lines (HCT-8/5-FU), the axis was shown to modulate drug sensitivity. High levels of LINC01296 correlated with increased survival during 5-FU treatment, while its inhibition sensitized cells to the drug (Panels E-H, M-P).

Conclusion and Future Directions

The LINC01296/miR-26a/GALNT3 axis represents a promising therapeutic target for CRC. While these in vitro results provide a clear mechanistic framework, future research must validate these findings in animal models and clinical cohorts. Overcoming the challenges of delivering RNA-based therapies remains a critical hurdle for translating these insights into effective patient treatments.

Summary updated

Abstract

In the publication of this article [1], there is an error in Fig. 5C (panel 4, group of InmiR-26a + silinc01296 in SW620). The revised Fig. 5 which includes 5C has now been included in this correction.
BibTeX
@article{liu2019correction,
  author = {Bing Liu and Shimeng Pan and Yang Xiao and Qianqian Liu and Jingchao Xu and Jia Li},
  title = {{Correction to: LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2019},
  doi = {10.1186/s13046-019-1367-9},
}
Figure